On 30 March, 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug ...

The FDA has granted a priority review to a new drug application (NDA) for lirafugratinib, a highly selective oral FGFR2 ...

Lirafugratinib, an oral FGFR2 inhibitor, receives FDA Priority Review for advanced cholangiocarcinoma with FGFR2 ...

-- With Priority Review designation, FDA set a Sept. 27 PDUFA date for approval decision -- Lirafugratinib achieved a 46.5% ORR, in CCA patients with FGFR2 fusion and rearrangement ...

Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of ...

TOKYO, Nov 20, 2024 - (JCN Newswire) - - Eisai Co., Ltd. announced today that it has launched fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor "TASFYGO Tablets 35mg" ...

Aberrations in fibroblast growth factor receptors FGFR2/3 are major drivers of many cancers-including intrahepatic cholangiocarcinoma, endometrial, breast, gastric, and bladder cancers. However, the ...

For years, developing selective FGFE2/3 inhibitors has been hindered by the extreme structural similarity among FGFR family members, leading to toxicities and resistance with current therapies.

WALTHAM, Mass. and BOULDER, Colo., Oct. 14, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (COGT) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically ...

Notably, Insilico’s self-developed Chemistry42 played a crucial role in this research by generating the pyrrolopyrazine carboxamide core as a starting point for further molecular design. Moreover, ...

Fibroblast growth factor receptors (FGFRs) are critical drivers of oncogenesis in various solid tumors, including urothelial carcinoma, hepatocellular carcinoma, ovarian cancer and lung adenocarcinoma ...